	US 11,911,407 B2
	Therapies for cardiomyopathy
Chris Watson, Dublin (IE); John Baugh, Dublin (IE); Mark Ledwidge, Cork (IE); and Ken McDonald, Dublin (IE)
Assigned to UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, Dublin (IE)
Filed by UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, Dublin (IE)
Filed on Apr. 17, 2018, as Appl. No. 15/955,628.
Application 15/955,628 is a division of application No. 14/893,920, abandoned, previously published as PCT/EP2014/060853, filed on May 26, 2014.
Claims priority of application No. 1309444 (GB), filed on May 25, 2013.
Prior Publication US 2019/0091253 A1, Mar. 28, 2019
Int. Cl. A61K 31/7064 (2006.01); A61K 31/706 (2006.01); A61K 31/713 (2006.01); C12Q 1/6883 (2018.01); G01N 33/50 (2006.01)

CPC A61K 31/7064 (2013.01) [A61K 31/706 (2013.01); A61K 31/713 (2013.01); C12Q 1/6883 (2013.01); G01N 33/5023 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/158 (2013.01); G01N 2500/02 (2013.01); G01N 2500/04 (2013.01); G01N 2500/10 (2013.01); G01N 2800/325 (2013.01)]

16 Claims

1. A method of treating a cardiomyopathy selected from the group consisting of hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and endomyocardial fibrosis comprising the step of administering to a patient in need thereof a hypomethylating agent, wherein the hypomethylating agent comprises 5-Azacytidine or 5-Aza-2′-Deoxycytidine, or a pharmaceutically acceptable salt of each thereof.